{"id":"46021","type":"article","url":"https://hartvaat.nl/2026/04/17/schildklierdisfunctie-en-hart-en-vaatziekten-ehj-overzicht/","title":"Schildklierdisfunctie en hart- en vaatziekten (EHJ-overzicht)","title_en":"Thyroid dysfunction and cardiovascular disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag248","source_url":"https://doi.org/10.1093/eurheartj/ehag248","authors":["Heba Alwan","Ola Hysaj","Baris Gencer","Leonidas Duntas","Nicolas Rodondi"],"significance":7,"published":"2026-07-13","source_date":"2026-04-17","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"Thyroid hormones regulate the cardiovascular system; both hypo- and hyperthyroidism are linked to dyslipidaemia, blood-pressure dysregulation, endothelial dysfunction, impaired cardiac function and arrhythmias. This EHJ review summarises the molecular and pathophysiological mechanisms and discusses the effect of levothyroxine in subclinical hypothyroidism on cardiovascular outcomes, which remains uncertain: the largest trial (TRUST) was underpowered but suggested a trend toward benefit. Recent omics and Mendelian-randomisation studies are also covered.","created":"2026-07-03T20:27:06Z","updated":"2026-07-04T19:27:02Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Schildklierhormonen reguleren het cardiovasculaire systeem; zowel hypo- als hyperthyreoïdie is gekoppeld aan dyslipidemie, bloeddrukontregeling, endotheeldisfunctie, verminderde hartfunctie en ritmestoornissen. Dit EHJ-overzicht vat de moleculaire en pathofysiologische mechanismen samen en bespreekt het effect van levothyroxine bij subklinische hypothyreoïdie op cardiovasculaire uitkomsten, dat onzeker blijft: de grootste trial (TRUST) was ondergemachtigd maar liet een trend richting voordeel zien. Ook recente omics- en mendeliaanse-randomisatiestudies komen aan bod.","abstract_original":"Thyroid hormones play an important role in regulating the cardiovascular system. Thyroid dysfunction, which encompasses hypothyroidism and hyperthyroidism, is relatively common and has been linked to a range of cardiovascular manifestations, including dyslipidaemia, abnormal blood pressure regulation, endothelial dysfunction, impaired cardiac function, and arrhythmias. The effects of levothyroxine replacement therapy on cardiovascular endpoints in subclinical hypothyroidism remain uncertain. The largest randomized controlled trial (TRUST) to date was underpowered to assess cardiovascular outcomes, although the results demonstrated a pattern towards a beneficial effect of levothyroxine. The aim of this review was to provide a summary of current knowledge on the relationship between thyroid dysfunction and cardiovascular health, with a focus on molecular and pathophysiological mechanisms underlying thyroid dysfunction and cardiovascular disease. Evidence from recent omics and Mendelian randomization studies is discussed, alongside an overview of the epidemiology of thyroid diseases and the impact of levothyroxine treatment on cardiovascular outcomes in subclinical hypothyroidism."}